✉news HealthMedicine first seen 3 h ago, last 2 h ago, peak #17
ALX Oncology publishes promising evorpacept gastric cancer trial data in Nature Medicine
Original: ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
ALX Oncology announced that Nature Medicine has published Phase 2 results from its ASPEN-06 trial, showing strong responses and durable clinical benefit with evorpacept combined with trastuzumab and chemotherapy in patients with HER2-positive gastric cancer. The publication adds peer-reviewed weight to the company's lead drug candidate and supports its ongoing development program in gastroesophageal cancers.
Why now: Investors and oncology specialists are following clinical progress for ALX Oncology's lead asset evorpacept.
ALX OncologyEvorpaceptNature MedicineASPEN-06 trial
Rank over time, top of the chart is #1. 2 snapshots from 3 h ago to 2 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/236678